Search bioRxiv⌕ Search

Biology subjects

Zygmunt, A.

Publications and source records attributed to Zygmunt, A..

2 recordsLinked to original sources

Single nucleus RNA sequencing of juvenile dermatomyositis skeletal muscle identifies altered angiogenic signaling

Juvenile dermatomyositis (JDM) is a chronic multisystem vasculopathy and inflammatory myopathy characterized by proximal muscle weakness, distinct rash, and risk of complications such as calcinosis cutis, skin ulceration, and mortality. Molecular insight from diagnostic muscle biopsy histology is limited, and the mechanistic pathoetiology of JDM remains poorly defined. We used single nuclei transcriptomics to assess muscle samples from patients with newly diagnosed treatment-naive JDM. As a control, we assessed muscle samples from patients with congenital (nemaline) myopathy (CM), a non-inflammatory disorder. A total of 25,794 high quality nuclei were analyzed and clustered into various muscle-resident or infiltrating cellular populations. JDM tissue was characterized by an enriched interferon (IFN) response signature across endothelial, stromal, and immune cell compartments. Endothelial and perivascular populations showed increased inflammatory and angiogenic programs. Intercellular communication inference analysis identified dysregulated vascular endothelial growth factor (VEGF)-related signaling involving endothelial, stromal, and myonuclear populations as a possible mechanism for myonuclear-driven modulation of the muscle microvasculature. Spatial RNA in situ hybridization supported increased expression of selected IFN responsive and angiogenesis signaling genes in JDM tissue. Collectively, these data provide a cell type-resolved view of treatment-naive JDM muscle and highlight vascular and IFN pathways for follow-up in larger cohorts.

genomics↗

Metabolic Collapse in Pancreatic Cancer via Combined Inhibition of Lactate Export and Thioredoxin Reductase

Pancreatic cancer is one of the most poorly prognosed types of cancer, with a low survival rate. Cancer cells exhibit altered and rapid metabolism, and in a process known as aerobic glycolysis, they metabolize glucose to lactate even in the presence of sufficient oxygen. Altered metabolism is a hallmark of cancer, making it a promising therapeutic target. There are many potential inhibitors of cancer cell metabolism, including auranofin and syrosingopine. Auranofin induces oxidative stress in cells by generating reactive oxygen species (ROS). Meanwhile, syrosingopine is an inhibitor of the two lactate transporters, MCT1 and MCT4, which contribute to intracellular acidification. Our studies demonstrated the high biological activity of the combination of auranofin and syrosingopine against pancreatic cancer in both in vitro and in vivo models. Our proposed mechanism of action for this drug combination is based on the simultaneous induction of oxidative stress and inhibition of lactate transporters, which consequently directs cancer cells to the apoptosis pathway.

cancer biology↗